San Francisco, CA -- (ReleaseWire) -- 12/09/2016 -- Therakine Ltd. announces the appointment of Mr. Steven B. Bettis as its Chief Executive Officer.

Mr. Bettis, who has been working with the company as a consultant for several months, brings 25 years of commercial and drug development experience to TheraKine, and was formerly the President and Co-founder of Eyetech Inc.

At Eyetech, Inc, which was established in 2008, Bettis lead a reorganization effort and reestablished the sustained release drug delivery program for Macugen, leading to an exit with Valeant Pharmaceuticals in 2012.

When asked about joining Therakine, Bettis said "I am very excited about the promising opportunity with TheraKine. There is growing need to ensure better compliance and improved efficacy while relieving the treatment burden for patients and physician offices – and local sustained release can solve these problems. Our proprietary drug delivery platform allows our pharmaceutical partners to utilize our technology to improve product delivery, or extend product life cycle. We look forward to revolutionizing how products are delivered in ophthalmology, dermatology, rheumatology and other therapeutic areas."

Bettis joins the company to lead transformative restructuring, financing, and new partnering opportunities.

Seth Yakatan, the outgoing CEO, says "It is a real pleasure to be handing the reins to Steve. I'm confident that he will lead the company through its next growth phases. We have worked to position the company for transformation from R&D into clinical phase, and recruiting Steve is an important and exciting milestone." Mr. Yakatan will stay with the firm as the interim CFO.

About TheraKine Ltd.
TheraKine Ltd., is a clinical stage pharmaceutical company utilizing a novel proprietary drug delivery system to significantly enhance and improve the therapeutic characteristics of new and approved drugs. Linear release kinetics for periods ranging from weeks to months are made possible without any changes to API, solvents or temperature extremes. Safety risks are reduced, as only GRAS excipients are used, and there are no polymerization or cross-linking steps. TheraKine partners with companies that need injectable or local sustained release formulations and has an internal pipeline of products in ophthalmology and dermatology.

For more information, please visit www.therakine.com.

Company contact:
Seth Yakatan
323-356-6321
seth@katanassociates.com

TheraKine Ltd.
500 S. Sepulveda Blvd. Suite 212
Manhattan Beach, CA 90266

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Francisco, CA -- (ReleaseWire) -- 11/04/2016 -- TheraKine Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 9474715, which enables innovative methods for locally injectable sustained release formulations of biologic and small molecule drugs with high concentration and superior injectability.

The formulation method for injectable sustained-release depots enables linear release of biologic drugs and small molecules over a period of weeks or months. No novel excipients are required, and there are no changes to the API, TheraKine's physics-based methods allow novel therapeutic modalities for many chronic medical conditions without introducing new regulatory or safety risks.

TheraKine's patent portfolio is growing, with both USA and EP allowances in process. CEO Seth Yakatan says, "As our patent portfolio continues to grow we are able to offer an expanded set of protected novel methods to partners with all classes of drugs. Combined with our internal programs, TheraKine is on a growth trajectory that is very exciting."

Scott Hampton, TheraKine's COO, shares that, "This method for formulating an injectable sustained release formulation has two key advantages, both of which are direct consequences of our physics-based approach. First, we are able to use GRAS excipients with long safety records, which takes a lot of regulatory and schedule risks off the table. Secondly, we are now able to do local injections with comparatively high drug loading, using very small needles, in some cases 27 or 29 gauge, which dramatically improves patient acceptance."

About TheraKine Ltd.
TheraKine Ltd. is a biopharmaceutical company focused on the use of biophysics to solve long-standing problems with sustained-release drug delivery. Linear release kinetics for periods ranging from weeks to months are made possible without any changes to API, solvents or temperature extremes. Safety risks are reduced, as only GRAS excipients are used, and there are no polymerization or cross-linking steps. TheraKine partners with companies that need injectable or local sustained release formulations and has an internal pipeline of products in ophthalmology and dermatology.

For more information, please visit www.therakine.com.

Company contact:
Seth Yakatan
323-356-6321
seth@katanassociates.com

TheraKine Ltd.
500 S. Sepulveda Blvd. Suite 212
Manhattan Beach, CA 90266

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Francisco, CA -- (ReleaseWire) -- 08/26/2016 -- TheraKine Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 86310619, a key patent for its innovative sustained-release formulation of injectable drugs.

The formulation method for hydrophobic injectable sustained-release depots enables linear release of biologic drugs and small molecules over a period of one to six months. Since no novel excipients are required, and there are no changes to the API, TheraKine's physics-based methods allow novel therapeutic modalities for many chronic medical conditions without introducing new regulatory or safety risks.

TheraKine's patent portfolio is growing, with several allowances pending, allowing the company to offer additional value to license partners. CEO Seth Yakatan says, "We believe we are the only company that offers months of linear release without polymers or chemical reformulation. The Patent Office's recognition is a significant step in our business strategy and will allow us to partner in almost every area of medicine."

Yakatan continued, "What is most exciting is that we have feasibility trials going with partners who have novel compounds which depend on local delivery with good kinetics, as well as with companies that are re-purposing off-patent compounds."

TheraKine's patent counsel, John Weatherspoon of Bibby, McWilliams & Kearney, has been guiding the firm's patent applications through domestic and international prosecution, and says, "This patent, and the several allowances in process, demonstrate that TheraKine's innovations are protectable and the overall portfolio strategy will result in a valuable contribution to the pharmaceutical industry."

"True linear release over several months creates new potential for old drugs and new ones," according to Dr. Andreas Voigt, TheraKine's Chief Scientist. "This addresses a real need and avoids the problems of older PLGA-type technologies."

About TheraKine Ltd.
TheraKine Ltd. is a biopharmaceutical company focused on the use of biophysics to solve long- standing problems with sustained-release drug delivery. Linear release kinetics for periods ranging from weeks to months are made possible without any changes to API, solvents or temperature extremes. Safety risks are reduced, as only GRAS excipients are used, and there are no polymerization or cross-linking steps. TheraKine partners with companies that need injectable or local sustained release formulations and has an internal pipeline of products in ophthalmology and dermatology. For more information, please visit http://www.therakine.com.

Company contact: Seth Yakatan

+1 (323) 356-6321 seth@katanassociates.com

TheraKine Ltd.
500 S. Sepulveda Blvd. Suite 212
Hermosa Beach, CA 90266

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm